BHST Overview

BioHarvest Sciences Inc. is a botanical synthesis company. The Company leverages its patented technology process to grow plant-based molecules, without the need to grow the underlying plant. It is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two business verticals: as a contract development and production organization on behalf of customers seeking complex molecules, and as a creator of nutraceutical health and wellness products, which include dietary supplements. Its segments include Nutraceuticals and Pharmaceuticals. VINIA is a red grape cell-based supplement, which is a commercial nutraceutical product derived from the Botanical Synthesis platform and is clinically proven to improve blood flow, which enhances physical energy and mental alertness. VINIA contains multiple polyphenols, including Piceid Resveratrol, which is 25x more soluble in water than regular resveratrol.

Wall Street analysts forecast BHST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHST is13.00 USD with a low forecast of 12.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

BioHarvest Sciences Inc revenue for the last quarter amounts to 8.51M USD, increased 8.23

BioHarvest Sciences Inc. EPS for the last quarter amounts to -0.12 USD, decreased -7.69

BioHarvest Sciences Inc (BHST) has 89 emplpoyees as of May 30 2026.

Today BHST has the market capitalization of 87.50M USD.